12 active not recruiting. 12 Phase 1, 6 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 12 | Active not recruiting 12 |
| Phase 2 | 6 | Active not recruiting 6 |
Follow Refractory Malignant Solid Neoplasm: new trials by email Literature Review of Refractory Malignant Solid Neoplasm trials Research Report on Refractory Malignant Solid Neoplasm
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors Atezolizumab, Biospecimen Collection, Computed Tomography - Atypical Teratoid/Rhabdoid Tumor, Epithelioid Sarcoma | Phase 1 / Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 86 | 2022-11-17 | 2026-07-14 |
| Elimusertib for the Treatment of Relapsed or Refractory Solid Tumors Elimusertib - Recurrent Alveolar Rhabdomyosarcoma, Recurrent Ewing Sarcoma | Phase 1 / Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 31 | 2021-12-22 | 2026-01-23 |
| Testing the Biological Effects of DS-8201a on Patients With Advanced Cancer Biopsy Procedure, Biospecimen Collection, Computed Tomography - Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 62 | 2020-09-01 | 2026-02-27 |
| Testing the Sequential Combination of the Anti-cancer Drugs Olaparib Followed by Adavosertib (AZD1775) in Patients With Advanced Solid Tumors With Selected Mutations and PARP Resistance, STAR Study Adavosertib, Olaparib - Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 13 | 2020-06-30 | 2026-09-30 |
| Avelumab and M6620 for the Treatment of DDR Deficient Metastatic or Unresectable Solid Tumors Avelumab, Berzosertib - Metastatic Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm | Phase 1 / Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 23 | 2020-03-17 | 2026-06-11 |
| FID-007 in Treating Participants With Advanced Solid Tumors Laboratory Biomarker Analysis, PEOX-based Polymer Encapsulated Paclitaxel FID-007, Pharmacokinetic Study - Advanced Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm | Phase 1 | Active not recruiting | University of Southern California | 50 | 2018-05-25 | 2026-04-29 |
| Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies Avelumab, Ivuxolimab, Radiation Therapy - Advanced Malignant Solid Neoplasm, Castration-Resistant Prostate Carcinoma | Phase 1 / Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 173 | 2017-08-02 | 2026-10-23 |
| M6620 and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery Berzosertib, Biopsy Specimen, Biospecimen Collection - Metastatic Colorectal Carcinoma, Metastatic Lung Small Cell Carcinoma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 66 | 2016-07-22 | 2026-09-25 |
| Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin Cisplatin, Methoxyamine, Pemetrexed Disodium - Advanced Malignant Solid Neoplasm, Advanced Peritoneal Malignant Mesothelioma | Phase 1 / Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 30 | 2016-03-08 | 2026-07-31 |
| Trametinib and Navitoclax in Treating Patients With Advanced or Metastatic Solid Tumors Biopsy Procedure, Biospecimen Collection, Computed Tomography - Metastatic Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm | Phase 1 / Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 96 | 2014-03-26 | 2026-09-11 |
| Cediranib Maleate and Selumetinib Sulfate in Treating Patients With Solid Malignancies Cediranib, Cediranib Maleate, Laboratory Biomarker Analysis - Metastatic Melanoma, Refractory Malignant Solid Neoplasm | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 19 | 2011-05-25 | 2026-09-10 |
| Riluzole and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors or Melanoma Laboratory Biomarker Analysis, Pharmacological Study, Riluzole - Advanced Malignant Solid Neoplasm, Recurrent Melanoma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 35 | 2011-02-18 | 2026-09-15 |
Neoplasm Metastasis (6) · Melanoma (2) · Chordoma (1) · Colorectal Neoplasms (1) · Lung Neoplasms (1) · Lymphoma (1) · Mesothelioma, Malignant (1) · Pancreatic Neoplasms (1) · Prostatic Neoplasms (1) · Rhabdoid Tumor (1) · Rhabdomyosarcoma, Alveolar (1) · Sarcoma (1) · Sarcoma, Ewing (1) · Small Cell Lung Carcinoma (1)
Neoplasms (11) · Neoplastic Processes (6) · Pathologic Processes (6) · Pathological Conditions, Signs and Symptoms (6) · Neoplasms by Histologic Type (5) · Neoplasms by Site (5) · Neoplasms, Germ Cell and Embryonal (3) · Lung Diseases (2) · Neoplasms, Connective and Soft Tissue (2) · Neoplasms, Nerve Tissue (2) · Neuroectodermal Tumors (2) · Neuroendocrine Tumors (2) · Nevi and Melanomas (2) · Respiratory Tract Diseases (2) · Respiratory Tract Neoplasms (2)
Specimen Handling (4) · Magnetic Resonance Spectroscopy (3) · Biopsy (2) · avelumab (2) · berzosertib (2) · 1,2-diaminocyclohexaneplatinum II citrate (1) · AZD 6244 (1) · BAY 1895344 (1) · Cisplatin (1) · Fluorodeoxyglucose F18 (1) · Irinotecan (1) · Paclitaxel (1) · Pemetrexed (1) · Phantoms, Imaging (1) · Pharmacogenomic Variants (1)
National Cancer Institute (NCI) (9) · M.D. Anderson Cancer Center (2) · University of Southern California (1)
United States (12) · Canada (2) · Australia (1)
Timothy A Yap (2) · Anthony El-Khoueiry, MD (1) · Aung Naing (1) · Brian A Costello (1) · Janice M Mehnert (1) · Liza C Villaruz (1) · Marianna Koczywas (1) · Mary F Wedekind Malone (1) · Michael V Ortiz (1) · Ryan B Corcoran (1) · Sarah Shin (1)
PMID 37036756, PMID 38270822, PMID 40139261, PMID 41646361
UM1CA186689 (2), UM1CA186717 (2), UM1CA228823 (2), P30CA006516 (1), P30CA014089 (1), P30CA015083 (1), P30CA072720 (1), P50CA127003 (1), R01CA149627 (1), U01CA062490 (1), U01CA069912 (1), U01CA132194 (1), UM1CA186686 (1), UM1CA186688 (1), UM1CA186690 (1)